Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Y. Gao (1) , B. Weenink , M. van den Bent , L. Erdem-Eraslan , M. Kros , Pae Sillevis Smitt , K. Hoang-Xuan (2) , A. Brandes , M. Vos (3) , F. Dhermain (4) , R. Enting , G.F. Ryan , O. Chinot (5) , M. Ben Hassel (6) , M.E. van Linde , W.P. Mason , J.M.M. Gijtenbeek , C. Balana , A. von Deimling (7) , Th Gorlia , R. Stupp , M.E. Hegi , B.G. Baumert , P.J. French

1 THU - Tsinghua University [Beijing]
2 CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière
3 IFIC - Instituto de Fisica Corpuscular
4 Service de Neuroradiologie [CHU de Bicêtre]
5 Département de neurooncologie
6 Service de radiothérapie
7 Ruprecht Karls University Heidelberg

Domains: Life Sciences [q-bio]

Y. Gao, B. Weenink, M. van den Bent, L. Erdem-Eraslan, M. Kros, et al.. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 2018, 94, pp.168 - 178. ⟨10.1016/j.ejca.2018.02.023⟩. ⟨hal-01814360⟩